Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Pacira BioSciences Inc (NASDAQ: PCRX) closed at $24.88 down -0.36% from its previous closing price of $24.97. In other words, the price has decreased by -$0.36 from its previous closing price. On the day, 0.5 million shares were traded. PCRX stock price reached its highest trading level at $25.135 during the session, while it also had its lowest trading level at $24.295.
Ratios:
For a deeper understanding of Pacira BioSciences Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.44. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.55.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on January 30, 2025, Upgraded its rating to Hold and sets its target price to $25 from $8 previously.
On August 13, 2024, Truist Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $30 to $8.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on August 12, 2024, whereas the target price for the stock was revised from $37 to $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 06 ’25 when GAUGLER DARYL bought 500 shares for $23.25 per share.
SLONIN JONATHAN sold 879 shares of PCRX for $16,174 on Jan 06 ’25. The Chief Medical Officer now owns 93,444 shares after completing the transaction at $18.40 per share. On Jan 06 ’25, another insider, SLONIN JONATHAN, who serves as the Officer of the company, bought 879 shares for $18.40 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1151351808 and an Enterprise Value of 1305590912. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.64 while its Price-to-Book (P/B) ratio in mrq is 1.48. Its current Enterprise Value per Revenue stands at 1.863 whereas that against EBITDA is 7.403.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.56, which has changed by -0.0706014 over the last 52 weeks, in comparison to a change of 0.07455289 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $31.67, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 0.67%, while the 200-Day Moving Average is calculated to be 25.90%.
Shares Statistics:
For the past three months, PCRX has traded an average of 945.57K shares per day and 1278700 over the past ten days. A total of 46.24M shares are outstanding, with a floating share count of 44.24M. Insiders hold about 4.39% of the company’s shares, while institutions hold 111.00% stake in the company. Shares short for PCRX as of 1743379200 were 5934152 with a Short Ratio of 6.28, compared to 1740700800 on 5859658. Therefore, it implies a Short% of Shares Outstanding of 5934152 and a Short% of Float of 18.65.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
